Literature DB >> 9407936

Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children.

J W Herms1, J Behnke, M Bergmann, H J Christen, R Kolb, M Wilkening, E Markakis, F Hanefeld, H A Kretzschmar.   

Abstract

PURPOSE: The expression of the c-erbB-2 oncogene was studied in childhood medulloblastoma to evaluate its prognostic value, which has been claimed previously. PATIENTS AND METHODS: Tumor material from 45 patients < 15 years old at diagnosis was studied using 3 monoclonal antibodies against the internal and external domains of the c-erbB-2 oncogene product.
RESULTS: Six of the 45 (13%) tumor specimens were found to be positive. C-erbB-2 expression was found more often in patients < 3 years old at diagnosis (4 of 15 patients, 27%) than in older patients (2 of 30, 6.6%). During the follow-up period (5.8 +/- 2.8 years) all patients with c-erbB-2 expression died of disease (after 1.2 +/- 0.7 years). Kaplan-Meier estimation revealed a highly significant correlation of c-erbB-2 expression and survival (p = 0.002). A further study of the expression of synaptophysin and the glial fibrillary acidic protein (GFAP) in the 45 tumors revealed a negative correlation of the expression of c-erbB-2 and these proteins.
CONCLUSION: C-erbB-2, which may be predominantly expressed by less differentiated tumors, was found to delineate a poorer prognostic subgroup, especially when diagnosed in patients < 3 years old.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407936     DOI: 10.1097/00043426-199711000-00004

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

Review 1.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 2.  Risk assignment in childhood brain tumors: the emerging role of molecular and biologic classification.

Authors:  Ian F Pollack; Jaclyn Biegel; Allan Yates; Ronald Hamilton; Sydney Finkelstein
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

Review 3.  Recent advances in embryonal tumours of the central nervous system.

Authors:  Chitra Sarkar; Prabal Deb; Mehar Chand Sharma
Journal:  Childs Nerv Syst       Date:  2005-01-29       Impact factor: 1.475

4.  Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression.

Authors:  Andrey Korshunov; Marina Savostikova; Sergey Ozerov
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

Review 5.  The rationale for targeted therapies in medulloblastoma.

Authors:  Tobey J MacDonald; Dolly Aguilera; Robert C Castellino
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

6.  Clinical and molecular stratification of disease risk in medulloblastoma.

Authors:  R Gilbertson; C Wickramasinghe; R Hernan; V Balaji; D Hunt; D Jones-Wallace; J Crolla; R Perry; J Lunec; A Pearson; D Ellison
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.